The retrospective design restricted standardized biomarker analyses, such as the absence of tumor-infiltrating lymphocyte quantification, PD-L1 expression scoring, and next-generation sequencing, thereby limiting our interpretation of mechanisms underlying differential responses. This evidence concerns the gene CD274 and neoplasm.